Novavax, Inc.
NVAX
$7.95
-$0.43-5.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 88.31M | 84.51M | 415.48M | 93.86M | 291.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.31M | 84.51M | 415.48M | 93.86M | 291.34M |
| Cost of Revenue | 119.58M | 147.38M | 152.39M | 150.29M | 278.46M |
| Gross Profit | -31.27M | -62.87M | 263.10M | -56.43M | 12.88M |
| SG&A Expenses | 73.34M | 66.95M | 101.00M | 82.30M | 155.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 213.79M | 214.33M | 253.39M | 232.59M | 474.91M |
| Operating Income | -125.48M | -129.82M | 162.10M | -138.73M | -183.57M |
| Income Before Tax | -73.58M | -122.33M | 164.59M | -145.29M | -176.70M |
| Income Tax Expenses | 7.45M | -1.03M | 2.21M | 2.26M | 1.69M |
| Earnings from Continuing Operations | -81.03M | -121.30M | 162.38M | -147.55M | -178.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.03M | -121.30M | 162.38M | -147.55M | -178.39M |
| EBIT | -125.48M | -129.82M | 162.10M | -138.73M | -183.57M |
| EBITDA | -112.96M | -117.12M | 173.23M | -126.58M | -172.77M |
| EPS Basic | -0.51 | -0.76 | 1.09 | -1.05 | -1.44 |
| Normalized Basic EPS | -0.47 | -0.46 | 0.70 | -0.62 | -0.89 |
| EPS Diluted | -0.51 | -0.76 | 0.99 | -1.05 | -1.44 |
| Normalized Diluted EPS | -0.47 | -0.46 | 0.62 | -0.62 | -0.89 |
| Average Basic Shares Outstanding | 160.24M | 160.05M | 148.38M | 139.92M | 123.68M |
| Average Diluted Shares Outstanding | 160.24M | 160.05M | 165.86M | 139.92M | 123.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
